Project information | Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer [ID3851] | Guidance

Status	Awaiting development
Process	TAG
ID number	3851

Provisional Schedule

Expected publication

10 May 2023

Timeline

Key events during the development of the guidance:

Date	Update
26 November 2021	Following a request received from the company, NICE will be undertaking an appraisal of Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer. This was originally terminated guidance TA564. The appraisal is expected to start during April 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-June 2022. The deadline for submissions is expected in approximately mid-August 2022.

Date

Update

26 November 2021

Following a request received from the company, NICE will be undertaking an appraisal of Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer. This was originally terminated guidance TA564. The appraisal is expected to start during April 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-June 2022. The deadline for submissions is expected in approximately mid-August 2022.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance